COMPARISON
Tirzepatide vs Vancomycin
5 attributes held for at least one of the two. 5 differ. Each value carries the register it came from and the date that register was read.
Answer
Tirzepatide is authorised or registered in 10 and Vancomycin in 9 of the 10 registers read. Tirzepatide: highest phase Phase 4 (after approval). Vancomycin: highest phase Phase 4 (after approval). 0 registered trials include both.
States no view on which is preferable, safer or more effective. Not medical advice.
| Tirzepatide | Vancomycin | |
|---|---|---|
| Registered trials differs | 309 clinicaltrials.gov · 2026-10-03 | 738 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | FDA-approved: MOUNJARO openfda · 2026-10-03T17:23:44.062Z | FDA-approved: Vancomycin Hydrochloride openfda · 2026-10-03T17:23:44.062Z |
| EU authorisation differs | Authorised ema · 2026-10-03 | Nothing on record ema read 2026-08-31 |
| EU authorised on differs | 2022-09-15 ema · 2026-10-03 | Not checked no record of "authorisedOn" for vancomycin |
| ATC code differs | A10BX16 ema · 2026-10-03 | Not checked no record of "atcCode" for vancomycin |
SIDE EFFECTS
Most common side effects, each beside its own placebo
| Side effect | Tirzepatide | placebo | Vancomycin | placebo |
|---|---|---|---|---|
| Nausea | 25.6% | 8.1% | 5.0% | 5.3% |
| Diarrhoea | 21.2% | 8.3% | 4.7% | 4.8% |
| Vomiting | 11.4% | 2.6% | 2.3% | 5.2% |
| Headache | 6.6% | 6.2% | 5.8% | 6.4% |
| Covid-19 | 15.5% | 16.0% | - | - |
| Constipation | 13.7% | 4.5% | - | - |
| Decreased appetite | 11.6% | 2.9% | - | - |
| Dyspepsia | 7.9% | 2.7% | - | - |
| Abdominal pain | 6.0% | 2.7% | - | - |
| Upper respiratory tract infection | 5.7% | 6.2% | - | - |
| Cough | - | - | 16.1% | 12.3% |
| Pyrexia | - | - | 5.0% | 4.4% |
Trial register Tirzepatide: 19 placebo-controlled trials; Vancomycin: 5. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Tirzepatide side effects · Vancomycin side effects
LEGAL STATUS
Approval in each country read
| Country | Tirzepatide | Vancomycin | Register |
|---|---|---|---|
| United States | FDA-approved | FDA-approved | Regulator FDA |
| European Union | Authorised | Not on the register | Regulator EMA |
| United Kingdom | Authorised | Authorised | Regulator MHRA |
| Canada | Authorised | Authorised | Regulator Health Canada |
| Australia | Registered | Registered | Regulator TGA |
| Switzerland | Authorised | Authorised | Regulator Swissmedic |
| Brazil | Registado | Registado | Regulator ANVISA |
| Serbia | Authorised | Authorised | Regulator ALIMS |
| Singapore | Registered | Registered | Regulator HSA |
| Turkey | Ruhsatli | Ruhsatli | Regulator TITCK |
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.